Consistency of medical abortion efficacy from 5 through 14 weeks' gestation.
OBJECTIVE
To assess the efficacy of medical abortion performed according to a single protocol from 5 through 14 weeks.


METHODS
Retrospective observational study of medical abortions through 14 weeks performed from January 2000 through August 2001. The protocol combined 400mg of mifepristone orally, followed 48 h later by 800 microg of misoprostol, administered vaginally, and repeated after 4 h if the patient did not begin to abort. Outcome measures were the abortion rate, the rates of immediate manual uterine revision and of secondary vacuum aspiration, the time to expulsion, the misoprostol dose, and analgesic use.


RESULTS
The study included 512 medical abortions. The abortion rate was 98.4% and the secondary vacuum aspiration rate 8.2%. The uterine exploration rate was 1.4%, but these occurred only at gestations above 13 weeks. The mean time to expulsion was 4.4+/-1.9 h (1-28), and the mean misoprostol dose 860+/-180 microg (0-2000). None of the characteristics studied differed significantly as a function of gestation. 1.6% of patients had complications.


CONCLUSIONS
Medical abortion was consistently effective through 14 weeks and can be offered as an alternative to the surgical technique.
Garbin
Olivier
O
Service de Gynécologie-Obstétrique, Hôpital CMCO-SIHCUS, CHU Strasbourg, 19, rue Louis Pasteur, 67300 Schiltigheim, France. olivier.garbin@sihcus.fr
Vayssiere
Christophe
C
Bettahar-Lebugle
Karima
K
Nisand
Israel
I
D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use*; D000021:Abortifacient Agents, Steroidal / Q000627:therapeutic use*; D000028:Abortion, Induced; D000293:Adolescent; D000328:Adult; D000818:Animals; D005260:Female; D006801:Humans; D008875:Middle Aged; D015735:Mifepristone / Q000627:therapeutic use*; D016595:Misoprostol / Q000627:therapeutic use*; D011247:Pregnancy; D011261:Pregnancy Trimester, First / Q000187:drug effects; D011262:Pregnancy Trimester, Second / Q000187:drug effects; D012189:Retrospective Studies; D016896:Treatment Outcome
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone